# Brian Hotchkiss

> Brian Hotchkiss is the Chief Business Officer of Bexorg, a Yale University spinout building the first integrated AI and whole-human-brain platform for central nervous system drug discovery. A chemical engineer turned biotech dealmaker, he spent nearly seven years at Stealth BioTherapeutics shaping corporate strategy and helping land a transformative Alexion collaboration, then served as Chief Business Officer at Protego Biopharma before joining Bexorg. He pairs four graduate-level degrees in engineering, biology, and business with a career spent translating hard science into partnerships, capital, and commercial strategy.

- **Role:** Chief Business Officer at Bexorg, Inc.
- **Organizations:** Bexorg, Inc., Protego Biopharma, Stealth BioTherapeutics, Ember Therapeutics, Pfizer
- **Nationality:** American
- **Education:** B.S. in Chemical Engineering, Cornell University, M.S. in Chemical Engineering, University of Iowa, M.S. in Biology, Brown University, M.B.A., University of Virginia Darden School of Business
- **Known for:** Helped shape corporate strategy and drive transactions during nearly seven years at Stealth BioTherapeutics, including the era of its transformative Alexion collaboration, Served as Chief Business Officer at Protego Biopharma, Leads business development and corporate strategy for Bexorg's first-of-its-kind whole-human-brain CNS discovery platform

## Career timeline

- **—** — Senior business development roles at Pfizer
- **—** — Senior business development roles at Ember Therapeutics
- **—** — Joined Stealth BioTherapeutics, spending nearly seven years in roles of increasing responsibility shaping corporate strategy
- **2019** — Stealth BioTherapeutics signs option collaboration with Alexion on elamipretide; Hotchkiss was part of the business team driving transactions in this era
- **—** — Served as Chief Business Officer at Protego Biopharma
- **2024** — Appointed Chief Business Officer at Bexorg, Inc., placed via Park Square Executive Search

## Achievements

- Helped shape corporate strategy and drive transactions during nearly seven years at Stealth BioTherapeutics, including the era of its transformative Alexion collaboration
- Served as Chief Business Officer at Protego Biopharma
- Leads business development and corporate strategy for Bexorg's first-of-its-kind whole-human-brain CNS discovery platform
- Earned four advanced/graduate-level degrees spanning chemical engineering, biology, and business

## Latest updates

- **2024-08** — Placed as Chief Business Officer at Bexorg via Park Square Executive Search, joining the Yale-spinout neuroscience company.
- **2025-10** — Bexorg associated with a roughly $23M raise within Series A funding; total funding around $43M, with Hotchkiss leading business development.

## Links

- Website: https://bexorg.com
- LinkedIn: http://www.linkedin.com/in/brianhotchkiss

---

Profile page: https://yespress.io/brian-hotchkiss
Published by YesPress — https://yespress.io
Last updated: 2026-06-14